Horizon Europe – Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Tuesday 14th, May 2024

External Deadline: Wednesday 22nd, May 2024


Actions under this topic must contribute to all the following expected outcomes:

  • Access for healthcare professionals to novel, robust and fit for purpose biomarkers with linked technologies enabling their use in clinical setting and progress towards validation. Biomarkers and linked technologies may be for diagnosis, monitoring disease progression, selecting the optimal therapeutic treatments, or assessing treatment response.
  • Availability for researchers of robust and fit-for-purpose biomarkers with linked technologies enabling their clinical use for diagnosing disease, disease monitoring, or monitoring treatment response. This will enable researchers to develop safer and more effective personalised treatments tailored to the individual’s characteristics and the stage of their disease. Alternatively, availability for researchers of key technology (e.g. companion diagnostics) that could be essential for the safe and appropriate use and selection of a corresponding drug or biological product or its development.
  • Availability for regulators of robust evidence on the suitability of selected biomarkers and their linked technologies to enable regulatory acceptance for a specific use.

See here for more information.

Closing Date: May 22, 2024 17:00:00 Brussels time

Funding Sources

Horizon Europe

This opportunity was posted by: RGCS

Last modified: April 4, 2024